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I. INTRODUCTION
Recently, the Federal Circuit and lower courts have applied a new
test to assess the question of obviousness for chemical compounds.
While courts have always considered the presence of some lead
compound to be relevant to the question of obviousness, beginning at
the turn of the millennium, the Federal Circuit began assessing
obviousness in a more formulaic fashion, applying what is commonly
referred to as the lead compound analysis to determine if a litigant has
*
B.S., Biochemistry, Kansas University, 2005; M.S., Chemistry, Kansas
University, 2008; J.D. Marquette University School of Law, 2011. Thanks to Professor Kali
Murray for her assistance in writing this article. Thanks as well to my family and, in
particular, to my husband, Steve.
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established a prima facie case of obviousness.
This Paper describes the development of the lead compound
1
2
analysis, and its application. This Paper then discusses some of the
3
shortcomings and weaknesses of the doctrine’s applications and how
understanding the lead compound analysis and how it is likely to be
applied in typical situations can be useful in understanding both how to
draft stronger patents and what ways might be available to attack the
obviousness of a chemical compound or a court’s application of the lead
4
compound analysis.
A. Obviousness and Chemical Compounds
While the obviousness analysis has always been factually intensive,
the parameters for assessing obviousness have remained relatively
steady since the United States Supreme Court first addressed
obviousness under the 1952 Patent Act in Graham v. John Deere
5
Company. In Graham v. John Deere the Supreme Court laid out four
factors for approaching obviousness. First, the scope and the content of
6
the prior art and the claims should be determined. Second, the
differences between the prior art and the claims at issue must be
ascertained. Third, the level of ordinary skill in the art is determined.
And finally, courts consider additional factors such as the commercial
7
success, long felt but unresolved needs, and failure of others.
The Supreme Court’s most recent take on obviousness emphasized
8
that the John Deere factors still defined the controlling inquiry. In KSR
v. Teleflex, the Supreme Court held that the Federal Circuit’s teaching
suggestion motivation (TSM) test was overly rigid and the Court
emphasized that any approach to obviousness must be a flexible
9
approach. Under the TSM test, the Federal Circuit would determine
obviousness of a combination by looking to see if the prior art had some
teaching, suggestion, or created some motivation to combine certain
10
elements in the way that the invention did. If a court found that the
1.
2.
3.
4.
5.
6.
7.
8.
9.
10.

See infra Part IA–IB.
See infra Part IC.
See infra Part II.
See infra Part III.
Graham v. John Deere Co. of Kansas City, 383 U.S. 1 (1966).
Id. at 17–18.
Id.
KSR Int’l Co. v. Teleflex, Inc., 550 U.S. 398 (2007).
Id. at 419.
Id. at 418.
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prior art did contain a teaching, suggestion or motivation, the invention
would be obvious.
The TSM test was a high standard for proving obviousness of a
chemical compound because it required the prior art to contain
language not often found, suggestions of what could be done. KSR
lowered the standard for asserting obviousness, holding that the Federal
Circuit’s standard was not the only approach to obviousness, and that
using it alone constituted too rigid of an analysis. After KSR, while a
teaching suggestion or motivation might be relevant, lower courts are
free to look at things outside the prior art, such as common sense and
11
ordinary creativity.
In the earliest cases at the Court of Customs and Patent Appeals
(C.C.P.A.) specific to chemical compounds, structural similarity was
12
deemed as sufficient to support a finding of obviousness. A person
who knew the structure of a related compound would then, in turn, be
motivated to make analogs of that compound. However, as technology
for elucidating structures came on the market, and more structures
became known, courts, perhaps recognizing the complexity and
13
unpredictability of chemical compounds, moved away from the
assumption that once a structure was known, it would be obvious to test
all the analogs for similar properties.
In the 1970s, the C.C.P.A. found that prior art disclosure of a
structural analog alone was insufficient to provide real motivation to
14
make a new compound. In Stemniski, the applicant claimed a tin
composition useful in lubricants as an antioxidant while the prior art
15
analog compositions had no known utility. The court decided that
without a known utility for the prior art compound, the applicant had no

11. Id. at 420 (“Common sense teaches, however, that familiar items may have obvious
uses beyond their primary purposes, and in many cases a person of ordinary skill will be able
to fit the teachings of multiple patents together like pieces of a puzzle.”).
12. See, e.g. In re Riden, 318 F.2d 761 (C.C.P.A 1963); In re Henze, 181 F.2d 196
(C.C.P.A. 1950).
13. Indeed, there are several examples of chemical compositions that are structurally
similar, but have widely diverging properties. A common example is thalidomide, a drug
developed in the 1950s. The drug contained two enantiomers, which are compounds that
differ only in their configuration at one site, that is, the atoms have the exact same
configuration. One enantiomer of thalidomide helped people suffering from insomnia to
sleep, however, the other enantiomer caused deformities in unborn children of the patients
who took the drug. See GARETH THOMAS, MEDICINAL CHEMISTRY: AN INTRODUCTION, 38
(2d ed. 2007).
14. In re Stemniski, 444 F.2d 581, 581 (C.C.P.A. 1971).
15. Id. at 582.
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reason or motivation to synthesize the claimed analogs. It was also
immaterial that the prior art compounds actually had these properties
17
since they were unknown at the time of invention.
18
A subsequent line of cases confirmed Stemniski. These cases
mainly conclude that some utility is required for the prior art compound
to give a person of ordinary skill in the art the requisite motivation to
19
synthesize analogs.
This new approach not only allowed for the
patenting of a large number of chemical compounds, but also confirmed
the idea that structural similarity for chemical compounds is more
unpredictable than the structural similarity of other systems. For
example, two mechanical structures with a substantially similar structure
are likely to operate in the same way, but chemical compounds do not
operate under this same assumption. In contrast, chemical compounds
display a wide range of properties from their steric effects to the
electronic effects of substitutions, as well their interactions with chiral
systems such as the body.
With the switch from the C.C.P.A. to the Federal Circuit, the
Federal Circuit considered what is still considered a lead case for the
obviousness of structurally similar chemical compounds en banc in In re
20
Dillon.
In Dillon, a patent applicant claimed a composition of
hydrocarbon fuel and tetra-orthoester, producing less soot during
combustion, but the prior art disclosed the use of tri-orthoesters in fuel
for dewatering purposes and of tetra-orthoesters as water scavengers in
hydraulic fluids. Tri-ortho esters differ from tetra-ortho esters in the
addition of one ester group to the compound. The Board of Patent
Appeals and Interferences found that the claims were prima facie
21
obvious in light of the prior art. The court found that the “sufficiently
close relationship” between the tri-orthoesters and the tetra-orthoesters and the knowledge within the prior art created an expectation
that the tetra-esters would have the same or similar properties as the tri22
esters.
The Federal Circuit summarized the analysis as having different
considerations: (1) “the new compound or composition [must be] []
16. Id. at 587.
17. Id.
18. See, e.g., In re Gyurik, 596 F.2d 1012, 1018 (C.C.P.A. 1979) (noting that a structural
analog was not obvious based on a reaction intermediate).
19. Id.
20. In re Dillon, 919 F.2d 688 (Fed. Cir. 1990).
21. Id. at 692.
22. Id.
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structurally similar to the reference compound or composition,” and (2)
that “there is some suggestion or expectation in the prior art that the
new compound or composition [would] [] have the same or similar utility
23
as [the compound asserted by the applicant] [].” If the previously
disclosed properties of a prior art compound provided sufficient
motivation to trigger a prima facie obviousness rejection, even though
the new compound has unrelated, different, and unexpected properties,
the analysis then turns to rebuttal, by showing that his compound has
unexpected properties relative to prior art compounds, “that the prior
art was so deficient that there was no motivation to make what
otherwise might appear to be obvious changes,” or any other pertinent
24
argument.
B. Development of Lead Compound Analysis
The earliest case establishing the modern “lead compound” analysis
25
is Yamanouchi Pharm. Co. v. Danbury Pharmacal, Inc. Yamanouchi
was the result of a successful motion for judgment as a matter of law
26
(JMOL) upholding the validity of the ‘408 patent. The ‘408 patent was
27
directed at compounds that inhibit gastric acid secretion. At issue was
28
a claim for the compound famotidine. Famotidine is a member of a
larger class of compounds called histamine2 (H2) antagonists, which have
a general structure containing a substituted heterocycle which is
29
connected to a polar tail by an “alkyl containing” chain. Danbury filed
an Abbreviated New Drug Application (ANDA) with the Food and
Drug Administration (FDA) and made a Paragraph IV certification that
30
the patent on famotidine was invalid. Paragraph IV certifications are
31
considered acts of infringement, and after receiving the certification,
Yamanouchi filed suit.
At the district court, Danbury argued that famotidine was invalid as
an obvious result of combining features of compounds from the prior
art, and then performing a bioisosteric substitution to reach resulting
23. Id.
24. Id. at 692–93.
25. Yamanouchi Pharm. Co. v. Danbury Pharmacal, Inc., 231 F.3d 1339 (Fed. Cir.
2000).
26. Id. at 1341.
27. Id.
28. Id.
29. Id.
30. Id. at 1342.
31. 35 U.S.C. § 271 (e)(2) (2010).
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32

compound. Specifically, Danbury presented two H2 antagonists from
the prior art, tiotidine and E44, and argued that famtotidine was the
result of combining the heterocylce of tiotidine with the polar tail of E44
followed by a routine bioisosteric substitution of a sulfomoyl group for a
33
carbamoyl
group
substitution
in
the
polar
tail.
The Federal Circuit upheld the JMOL noting at the outset that
Danbury did not show the motivation for selecting either of the
34
compounds. While the E44 showed increased activity, the court noted
that the activity alone was not a sufficient motivation to choose E44 as a
lead compound because other compounds had been shown to be more
35
active. The court further noted that Danbury had failed to show the
motivation to combine the heterocycle of tiotidine with the polar tail of
36
E44. An expectation that the compound would show baseline H2
antagonist activity was not enough to show the reasonable expectation
37
of success for the compound. Finally, the court noted that the prior art
did not suggest any order of manipulating the compounds, so there was
no teaching that would have led a person having ordinary skill in the art
to follow the steps of combining the two parts of different molecules,
then making the bioisosteric substitution.

The analysis in Yamanouchui was applied again in Eli Lilly & Co. v.
Zenith Goldline Pharm., Inc.; however, in Lilly the analysis of
Yamanouchi was transformed into a requirement. In Lilly, IVAX
Pharmaceuticals, Inc. (formerly Goldline) filed an ANDA Paragraph IV
32.
33.
34.
35.
36.
37.

Yamanouchi, 231 F.3d at 1343–44.
Id.
Id. at 1345.
Id.
Id.
Id.
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certification to make Lilly’s Zyprexa. IVAX asserted that Lilly’s patent
38
on the active ingredient in Zypreza, olanzapine, was invalid as obvious.
IVAX argued that olanzapine was obvious based on a prior art
reference to ethyl olanzapine. Ethyl olanzapine has a similar structure
to olanzapine differing only in that ethyl olanzapine has an ethyl rather
than a methyl group on the thiophene ring.

IVAX argued that the structural similarity made them prima facie
obvious, but the district court rejected IVAX’s arguments. Instead, the
district court applied the two step analysis from Yamanouchi to
39
determine whether there was a prima facie case of obviousness. On
appeal, IVAX argued that the district court had erred by requiring as a
“threshold requirement” a teaching or incentive to treat the closest
40
prior art as a lead compound. The Federal Circuit affirmed the
decision below and likened the case to Yamanouchi; however, unlike
the district court, the Federal Circuit did not cite Yamanouchi as the
source of its two step analysis. Despite not citing Yamanouchi in the
same way as the district court, the Federal Circuit undertook the same
analysis as the district court finding first that IVAX had failed to prove
that ethyl olanzapine was the lead compound. Despite its structural
similarity, the prior art had taught that an electron withdrawing group
41
on the benzene ring improved activity. Next, the court further noted
that even if ethyl olanzapine would have been a lead compound, the law
required motivation to modify the prior art compound into the claimed
42
invention.
38.
2006).
39.
2005).
40.
2006).
41.
42.

See Eli Lilly & Co. v. Zenith Goldline Pharm., Inc., 471 F.3d 1369, 1380 (Fed. Cir.
Eli Lilly & Co. v. Zenith Goldline Pharm., Inc, 364 F. Supp. 2d 820, 904 (S.D. Ind.
Eli Lilly & Co. v. Zenith Goldline Pharm., Inc., 471 F.3d 1369, 1377 (Fed. Cir.
Id. at 1374.
Id. at 1379.
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The Federal Circuit gave more clarity to the new requirement in
Takeda Chemical Industries, Ltd v. Alphapharm. In Takeda,
Alphapharma challenged the validity of Takeda’s patent on
Thiazolidinedione
derivates
on
the
grounds
of
43
obviousness. Thiazolidinedione compounds (TZDs) are a class of
compounds which were first discovered to be useful for the treatment of
Type 2 diabetes because they have biological activity against insulin
resistance. Claim 2 of the patent referred to pioglitazone, which later
became the active ingredient of Takeda’s drug ACTOS, which is used to
44
control blood sugar in patients with Type 2 diabetes.
Alphapharm’s validity challenge rested on a prior art reference,
compound b, which showed a compound that differed from pioglitazone
in that the pyridyl ring was substituted with a methyl rather than an
ethyl, and that the substitution was at the six position of the ring, rather
45
than at the five position. The district court ruled in favor of Takeda
finding that the claims were not obvious because there was no
motivation to select compound b as the lead compound for antidiabetic
46
research and that the prior art taught away from its use.

Alphapharm appealed, arguing that the lower court misapplied the
holding of In re Dillon, which said that the structural similarity between
compounds could create a prima facia case of obviousness. The Federal
Circuit elaborated on the requirements of structural similarity, noting
that “[s]tructural relationships may provide the requisite motivation or
suggestion to modify known compounds to obtain new compounds” but
a prima facie case of unpatentability required “a showing that the prior
art would have suggested making the specific molecular modifications

43. Takeda Chem. Indus., Ltd. v. Alphapharm Pty., Ltd., 492 F.3d 1350, 1354 (Fed.
Cir. 2007).
44. Id. at 1353–54.
45. Id. at 1354.
46. Id.
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47

necessary to achieve the claimed invention.” The court then restated
saying, “in cases involving new chemical compounds, it remains
necessary to identify some reason that would have led a chemist to
modify a known compound in a particular manner to establish prima
48
facie obviousness.”
Applying this rule to the facts at issue, the court found that
Alphapharm had failed to make a showing that compound b would have
been selected as a lead compound. The court clarified that by lead
compound, Alphapharm was referring to “a compound in the prior art
that would be most promising to modify in order to improve
49
upon.” The court looked at several prior art references, some of which
suggested that compound b was particularly important, and some of
which did not. The court found that as a whole, the person of ordinary
skill in the art would not have selected compound b as a lead
50
compound. The court went on to note that even if Alphapharm had
established the preliminary finding that compound b was a lead
compound, there was nothing in the prior art that suggested the
modifications of changing the ethyl substituent to the methyl substituent
51
and moving the placement of the substituent.
Subsequent cases cite Takeda for the required lead compound
analysis; however, commentators have suggested that the true origin of
the required showings stems from Yamanouchi, where the obviousness
challenge was so absurd that the court was merely pointing out in dicta
52
the flawed logic of the challenging party.
Dicta or not, the lead
compound analysis has taken firm root with several other Federal
Circuit cases applying the doctrine and cases at the district court level as
53
well.
47. Id. at 1356 (quoting In re Deuel, 51 F.3d 1552, 1558 (Fed. Cir. 1995)).
48. Id. at 1357 (emphasis added).
49. Id.
50. Id. at 1360.
51. Id. at 1361.
52. Vincent Capuano, Obviousness of Chemical Compounds: The “Lead Compound”
Concept, INTELLECTUAL PROPERTY TODAY, July 2007, at 33.
53. See Proctor & Gamble Co. v. Teva Pharm., USA, Inc., 566 F.3d 989 (Fed. Cir.
2009); Sanofi-Synthelabo v. Apotex, Inc., 550 F.3d 1075 (Fed. Cir. 2008); Ortho-McNeil
Pharm., Inc. v. Mylan Lab., Inc., 520 F.3d 1358 (Fed. Cir. 2008); Eisai Co. Ltd v. Dr. Reddy
Lab., 533 F.3d 1353 (Fed. Cir. 2008); Altana Pharma AG v. Teva Pharm. USA, Inc., 566 F.3d
999 (Fed. Cir. 2009); Pfizer, Inc. v. Apotex, Inc., 488 F.3d 1377 (Fed. Cir. 2007); Eli Lilly &
Co. v. Sicor Pharm., Inc., 705 F. Supp. 2d 971 (S.D. Ind. 2010); Pfizer Inc. v. IVAX Pharm.,
Inc., No. 07-CV-00174 DMC, 2010 WL 339042 (D.N.J.); Sanofi Aventis Deutschland GMBH
v. Glenmark Pharm., Inc., No. 07-CV-5855DMC, 2010 WL 2428561 (D.N.J.); Unigene Lab.,
Inc. v. Apotex, Inc., No. 06 CV.5571 2009 WL 2762706 (S.D.N.Y.); Eli Lilly & Co. v. Actavis
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C. Current Application of the Lead Compound Analysis
Since its development several cases have shed light on the nuances
of the lead compound analysis. In its simplest form, in order to find a
chemical compound obvious, a party must prove first that a person of
ordinary skill would have selected the compound as a lead compound.
Second, it must be proved that the person of ordinary skill in the art
would have had some motivation to modify the lead compound. Finally,
a court will weigh rebuttal evidence. The nuances, as well as some gaps
in the doctrine have been shown by subsequent case law where the
54
doctrine has been invoked.
1. Selection of the Lead Compound
The party challenging the obviousness of a chemical composition
55
must first establish a lead compound. The Federal Circuit defined lead
compound in Takeda as a compound in the prior art that would be
56
“most promising to modify” to obtain better activity. A compound
which has been singled out in its field is more likely to be considered to
be a lead compound; whereas negative side effects can sway the court
against finding that the compound was a lead compound. A party
challenging obviousness is more likely to prevail when there are a small
number of lead compounds, but is not limited to a single lead
57
compound.
In Altana Pharma AG v. Teva Pharmaceuticals USA, Inc., the
Federal Circuit affirmed a district court’s determination that a
compound was a lead compound because the compound was identified
58
as the most active in the field. The dispute centered around Altana’s
Elizabeth LLC, 676 F.Supp. 2d 352 (D.N.J.); Merck Sharp & Dohme Pharm. v. Teva Pharm.
USA, Inc., No. 07-1596 2009 WL 3153316 (D.N.J.); Bayer AG v. Dr. Reddy’s Lab., Ltd., 518
F. Supp. 2d. 617 (D. Del. 2007); Daiichi Sankyo Co. Ltd. v. Mylan Pharm., Inc., 670 F. Supp.
2d. 359 (D.N.J.); In re ’318 Patent Infringement Litigation, 583 F.3d 1317 (Fed. Cir. 2009);
Novartis Pharms. Corp. v. Teva Pharm. USA, Inc., No. 05-CV-1887, 2007 WL 2669338
(D.N.J); Pfizer v. Teva Pharms. USA, Inc., 482 F. Supp. 2d. 390 (D.N.J.); Janssen Pharm. v.
Mylan Pharm., Inc., 456 F. Supp. 2d 644 (D.N.J.).
54. See infra Section II.
55. Contentions by parties to the contrary have been rejected by courts. In Bayer AG
v. Dr. Reddy’s Laboratories, Dr. Reddy’s attempted to argue that it did not need to establish
a lead compound and did not have any testimony on the subject. The court disagreed and
required a lead compound. 518 F. Supp. 2d 617, 626–27 (D. Del. 2007).
56. See Takeda Chem. Indus., Ltd. v. Alphapharm Pty., Ltd., 492 F.3d 1350, 1357 (Fed.
Cir. 2007).
57. Eisai Co. Ltd v. Dr. Reddy’s Lab., Ltd., 533 F.3d 1353 1358–59 (Fed. Cir. 2008).
58. Altana Pharma AG v. Teva Pharms. USA, Inc., 566 F.3d 999, 1008 (Fed. Cir.
2009).
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patent on pantoprazole, the active ingredient in, PROTONIX®.
Pantoprazole is a proton pump inhibitor (PPI) and was developed after
60
AstraZeneca had successfully marketed another PPI, omeprazole.
Teva argued that the patent on pantoprazole was invalid in light of both
Altana’s own patent disclosing a similar compound, compound 12, and
61
AstraZeneca’s patent on omeprazole. The district court found that a
person of ordinary skill in the art would have selected compound 12 as a
62
lead compound. The Federal Circuit affirmed, finding that the district
63
court’s decision was not clearly erroneous, despite the fact that Altana
produced evidence that there were concerns about the toxicity of
compound 12, and that there were over ninety other compounds
64
disclosed by the prior art. The district court based its decision on
evidence that compound 12 was the natural choice for further
development because it had a higher potency than any of the other
65
compounds.
The opposite decision was reached in Takeda v. Alphapharm where
66
the parties presented multiple prior art references.
Some of the
references identified compound 12 as important, while other references
identified different compounds as important. The court also found
references discussing the side effects of compound 12 noting that
“negative properties . . . would have directed one of ordinary skill in the
67
art away from that compound.”
The number of potential lead compounds is also important to the
lead compound analysis. In Ortho-McNeil Pharmaceutical v. Mylan,
68
Mylan challenged Ortho-McNeil’s patent on topiramate. Although
topiramate’s anticonvulsant properties had been discovered by chance
while a scientist was looking for a diabetes drug, Mylan argued that a

59. Id. at 1002.
60. Id. at 1003.
61. Id. at 1004–05.
62. Id. at 1005.
63. Id. at 1010.
64. Id. at 1008.
65.
Id. (“Although potency is not dispositive, the district court believed–not
unreasonably–that the potency of the compound was a factor that would have led one of skill
in the art to select compound 12 from the group for further study. It bears mention that
Altana itself had selected compound 12 for further development efforts.”).
66. Takeda Chem. Indus., Ltd. v. Alphapharm Pty., Ltd., 492 F.3d 1350 (Fed. Cir.
2007).
67. Id. at 1359.
68. Ortho-McNeil Pharm. Inc. v. Mylan Lab., Inc., 520 F.3d 1358, 1361 (Fed. Cir.
2009).
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person of ordinary skill in the art of searching for a diabetes drug would
have found topiramate. The Federal Circuit disagreed stating that,
“[t]he record . . . does not present a finite (and small in the context of
the art) number of options.” But that an “easily traversed, small and
finite number of alternatives . . . might support a conclusion of
69
obviousness.”
While a small number of lead compounds can be advantageous in
convincing a court that the person of ordinary skill would have selected
a lead compound, parties are not limited to only one lead compound. In
Eisai v. Dr. Reddy’s Laboratories, Ltd, Teva, along with Dr. Reddy’s,
challenged Eisai’s patent on rabeprazole, a proton pump inhibitor
70
developed in the wake of the commercial success of omeprazole.
Teva’s invalidity claim rested on both omeprazole and another
71
compound. After the district court found rabeprazole nonobvious,
Teva appealed, arguing that the district court erred in making it choose
a single lead compound. The Federal Circuit contended that Teva, not
the district court, chose to limit its case to a single lead compound and
again noted that the prima facie case for non-obviousness was consistent
72
with KSR.
2. Motivation to Modify the Lead Compound
Once a lead compound has been established, the party asserting that
a chemical compound is obvious must show some motivation to modify
73
the lead compound in a way that results in the compound at issue. The
motivation to modify the lead compound can come from an explicit
teaching in the prior art, or can be gleaned from the prior art as a whole.
As with the selection of the lead compound, the number of possibilities
for modification can be important; however, the modification cannot be
the result of mere routine testing. Finally, to make the prima facie case
of obviousness, there must be some reasonable expectation that the
modification will work.
Motivation to modify a prior art compound can come from explicit
references in the prior art.
In Altana Pharma AG v. Teva
Pharmaceuticals, the Federal Circuit affirmed the district court’s finding
that articles within the prior art would have led a person to modify the
69.
70.
71.
72.
73.
2007).

Id. at 1364.
Eisai Co. v. Dr. Reddy’s Lab., Ltd., 533 F.3d 1353, 1360 (Fed. Cir. 2008).
Id. at 1357.
Id. at 1358–59.
Takeda Chem. Inds., Ltd. v. Alphapharm Pty., Ltd., 492 F.3d 1350, 1357 (Fed. Cir.
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74

asserted lead compound. One of the prior art articles suggested that a
pKa of 4 would be most desirable for a proton pump inhibitor because it
would improve the stability prior to the compounds introduction to the
75
parietal cells in the stomach. Another reference suggested that the
specific substitution made in transforming the lead compound,
substituting a methoxy group for a methyl group would provide a lower
pKa. The Federal circuit found that this evidence supported the district
court’s finding that a person of ordinary skill in the art would have
76
found the modifications to the lead compound obvious.
Courts have also found motivation to alter the lead compound in the
absence of a specific teaching. In Pfizer v. Apotex, Apotex challenged
77
the validity of Pfizer’s patent on the compound amlodipine besylate.
Amlodipine besylate is the besylate salt of amlodipline, a compound
78
The prior art also discussed
which had previously been patented.
pharmacologically acceptable salts of amlodipine, but never the besylate
79
salt specifically. The Federal Circuit overturned the district court’s
finding of non-obviousness. The Federal Circuit noted that consistent
with KSR, motivation could “be gleaned” from the prior art as a whole.
There were a limited number of pharmacologically acceptable salts, and
besylate was known to have favorable properties; thus, a person of
ordinary skill in the art would have found it obvious to modify
amlodipine to its beslyate salt.

In Pfizer v. Apotex, the court also noted that the discovery of the
74.
75.
76.
77.
78.
79.

Atlana Pharma AG v. Teva Pharm. USA, Inc., 566 F.3d 999, 1008 (Fed. Cir. 2009).
Id. at 1004.
Id. at 1010.
Pfizer, Inc. v. Apotex, Inc., 480 F.3d 1348, 1352 (Fed. Cir. 2007).
Id. at 1353.
Id. at 1361.
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besylate was the product of routine testing and thus did not meet the
standards of patentability. While the court noted that in the last
sentence of 35 U.S.C. § 103, “[p]atentability shall not be negatived by
80
the manner in which the invention was made,” the court noted that
consideration of the “routine testing” by Pfizer was appropriate because
it provided both the means and the likely results of trying the compound
81
with acceptable salts. The court likened the choosing of the salt to
optimization of a reaction which flows from the “‘normal desire of
82
scientists . . . to improve upon what is already . . . known.’”
3. Likelihood of Success
Finally, the cases have also established that in addition to the
motivation to modify the lead compound, there must be some likelihood
of success in modifying the lead compound. A showing that the field
was highly unpredictable can weigh against a prima facie case.
In Proctor & Gamble v. Teva Pharmaceuticals, Teva challenged P &
G’s patent on the compound risedronate as obvious in light of another
patent that disclosed thirty-six other molecules for preventing bone
83
resorption.
Teva argued that the structural similarity between
risedronate and the prior art compound, 2-pyr EDHP would have made
84
risedronate obvious to a person of ordinary skill in the art.

Risedronate and 2-pry EHDP are positional isomers, differing in the
placement of only position. The district court found that 2-pyr-EHDP
was not likely to be selected as a lead compound because there were a
80.
81.
82.
83.
2009).
84.

35 U.S.C. § 103 (2010).
Pfizer, 480 F.3d at 1367.
Id. at 1368.
Proctor & Gamble Co. v. Teva Pharm. USA, Inc., 566 F.3d 989, 993 (Fed. Cir.
Id.
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number of other compounds disclosed in the ‘406 patent, and 2-pyr
85
EDHP was not specifically claimed. Other prior art had suggested the
concept of testing the positional isomers but the court found that these
modifications would not have been obvious in the field of
86
bisphosponates due to their unpredictability. The Federal Circuit
affirmed, while the court noted that a compound may provide the
motivation to try its isomer, analog or homolog, in this case there was
insufficient evidence for a person of ordinary skill to test risedronate
87
due to the unpredictability of the field. The court concluded that Teva
had also failed to show that a person of ordinary skill in the art would
have had a reasonable expectation of success in synthesizing
88
risedronate.
In Pfizer v. Apotex, the court overturned the district court’s finding
that a skilled artisan would not have had a reasonable expectation of
success in making the besylate salt of amlodipine. Pfizer had presented
evidence at the trial that there was no reliable way to predict whether a
salt would form and what its exact properties would be. The court
noted that “obviousness cannot be avoided simply by a showing of some
degree of unpredictability in the art so long as there is some reasonable
89
probability of success.”
A compound’s unexpected positive properties can rebut the
presumption. In Sanofi-Synthelabo v. Apotex, the court found that a
patent for a single enantiomer of a lead compound was not obvious
90
because the separation produced unexpected results. The compound
at issue in Sanofi-Synthelabo was the d-enantiomer of clopidogrel
bisulfate. The racemic mixture of clopidogrel had previously been
patented by Sanofi-Synthelabo. The court found that the racemate
would have been identified as a lead compound by a person of ordinary
91
skill in the art despite problems with its toxicity. Sanofi-Synthelabo
decided to undertake the separation of the enantiomers and found
absolute stereoselectivity, meaning that the d-enantiomer showed all the
favorable therapeutic activity while the l-enantiomer showed all of the

85. Proctor & Gamble Co, v. Teva Pharm. USA, Inc., 536 F. Supp. 2d. 476, 495 (D.
Del. 2008).
86. Id.
87. Proctor & Gamble Co., 566 F.3d at 995.
88. Id. at 996.
89. Id. at 1364.
90. Sanofi-Synthelab v. Apotex, 550 F.3d 1075, 1090 (Fed. Cir. 2008).
91. Id. at 1080.
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92

toxicity.
Apotex appealed arguing that the district court had applied an
incorrect legal standard and should have asked not whether the results
were unexpected, but rather, whether or not it would be obvious to try
93
to separate the enantiomers. The Federal Circuit affirmed, noting that
a person of ordinary skill would not have expected absolute
94
stereoselectivity.
The opposite result was reached when stereoisomers were separated
in the absence of unexpected results. In Aventis Pharma Deutschland
GMBH v. Lupin, Ltd., a claim to the pure S enantiomer of a ACE
95
inhibitor was found to be obvious. The prior art had disclosed related
ACE inhibitors and the fact that the all-S configurations were more
96
97
potent. The court determined that the patent was obvious.
Finally, if the case of obviousness is sufficiently strong, no rebuttal
evidence will be able to overcome it. In Pfizer v. Apotex, after finding
that a prima facie case of obviousness for amlodipine besylate had been
made, the Federal Circuit rejected Pfizer’s argument that unexpected
results overcame the prima facie case. The court noted that even if
Pfizer had presented unexpected results, it would not have overcome
98
the strong case of obviousness.
II. PROBLEMATIC ASPECTS OF LEAD COMPOUND ANALYSIS
The lead compound analysis is problematic in several ways. First,
lower courts are often confused by the test, and its limits are not well
understood. Second, the test is exactly the type of rigid application that
the Supreme Court warned against in KSR v. Teleflex. Moreover, the
test fails to consider some of the realities of drug development in
important aspects such as synthesis.
Several aspects of its application are still problematic even as the
lead compound analysis is becoming more solidified in the case law.
One main problem with the test is that its limits are not clearly defined
by the Federal Circuit and lower courts have applied the doctrine to
cases where it is not clear that structural similarity is more at issue or at
92. Id. at 1081.
93. Id. at 1089.
94. Id. at 1087.
95. Aventis Pharma Deutschland GMBH v. Lupin, Ltd., 499 F.3d 1293, 1294–95 (Fed.
Cir. 2007).
96. Id. at 1296.
97. Id. at 1303.
98. Pfizer, Inc. v. Apotex, Inc., 480 F.3d 1348, 1381 (Fed. Cir. 2007).
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least not the only issue. Another problem which has been addressed, but
only in a cursory fashion, is whether the lead compound analysis, which
is highly rigid and formulaic, comports with the requirements for any
obviousness analysis from KSR, which is that the approach must be
flexible.
A. Application to Combination Drugs
In
Sanofi-Aventis
Deutschland
GMBH
v.
Glenmark
Pharmaceuticals, the District Court of New Jersey used the lead
99
compound approach to assess the obviousness of a combination drug.
A combination drug, sometimes also called a fixed dose combination,
100
combines two or more pharmaceutical agents in a single drug. Most
pharmaceuticals traditionally have only one active ingredient.
Combination drugs have become increasingly popular—some because
the two drugs work synergistically, also doctors sometimes prefer
101
combination drugs because they increase compliance.
In Sanofi Aventis Deuschland GMBH v. Glenmark Pharmaceuticals,
Aventis sought to enjoin Glenmark from selling a generic form of
Tarka®, a hypertension drug.
Tarka® combines trandolapril,
immediate release angiotensin converting enzyme inhibitor, and
verapamil hydrochloride, a slow release formulation of a calcium
channel blocker. Thus, it has two separate components, whose
structures are as follows.

99. Sanofi-Aventis Deutschland GMBH, v. Glenmark Pharm. Inc., USA, No. 07-CD5855 DMC, 2010 WL 2428561 (D.N.J.).
100. Popular examples of combination therapies include Symbyax® which combines
Zyprexia® and Prozac®, and Caduet®, which combines Lipitor® for high cholesterol and
Norvasc® for hypertension.
101. See Fing Pan et al., Impact of Fixed-Dose Combination Drugs on Adherence to
Prescription Medications, 23(5) J. Gen. Internal Med., 611 (2008) (discussing the number of
medications prescribed as one of many factors affecting patient compliance with a prescribed
regimen). For a study of patients views on the benefits of combined pills versus multiple
medications see generally B. Williams et al., Patient Perspectives on multiple medications
versus combined pills: a qualitative study, 98 QJM 885 (2005).
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Sanofi’s Patent claimed combinations of an angiotensin-converting
inhibiter with calcium agonists in drugs. Angiotensin converting
enzyme is an enzyme in the body that mediates, vasoconstriction, by
converting angiotensin I to angiotensin II and by degrading bradykinin,
102
a vasodilator.
An angiotension converting enzyme agonist is a
molecule that binds to the Angiotensin converting enzyme to reduce its
103
activity. Several compounds act as ACE inhibitors, but the patent
claimed a two specific ACE inhibitors quinapril and trandolapril.
Calcium channel blockers disrupt the flow of Calcium ions in the body.
In blood vessels, decreased calcium results in less contraction of the
vessels and increase arterial flow. Again, several compounds are known
to act as calcium channel blockers and the patent was not restricted to
104
any certain inhibitor.
In assessing Sanofi’s request for an injunction, the District Court for
New Jersey applied the lead compound analysis in determining the
102. Boron Walter, Ph.D. Medical Physiology, A Cellular and Molecular Approach,
886–87, 1059 (2003).
103. For example, benazepril, captopril, enalapril, fosinapril, lisinopril, moexipril,
perindopril, quinapril, ramipril, trandolapril.
104. Sanofi-Aventis Deutschland GMBH, 2010 WL 2428561, at *11. Examples
include amlodipine, aranidipine, azelnidipine, barnidipine, benedipine, bepridil, clinidipine,
clevidipine, diltazem, fendilinem, isradipine, efonidipine, felodipine, fluspirilene, gallopamil,
lacidipine, lercanidipine, manidipine, mibefradil nicardipine, nifedipine, nivadipine,
nimodipine, nisolidipine, nitrerdipine, pranidipine, verpamil.
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105

likelihood of success on the merits.
In assessing the likelihood of
success on the defense of obviousness, the court invoked the lead
compound analysis. Citing Takeda, the court noted that “in cases
involving new chemical compounds, . . . it remains necessary to identify
some reason that would have led a chemist to modify a known
compound in a particular manner to establish prima facie obviousness of
106
a new claimed compound.”
The court then went on to assess the
relevant prior art, which included (1) a prior art reference suggesting the
ACE inhibitor captopril with a calcium agonist, (2) a different ACE
inhibitor, enalapril with a calcium agonist nifedipine, (3) a reference
teaching that quinapril was “considerably more potent” than either
107
elanopril or catopril.
The court found that the likelihood of success on the merits favored
Glenmark, and that the prior art weighed toward a finding of
obviousness. While Sanofi asserted that there were important structural
108
differences between enalapril, quinapril, and captopril, the court
rejected this argument, but on the basis that the ‘244 patent did not
purport to resolve the problems of structure or ACE or mechanism of
109
action of the ACE inhibitor.
The court also gave little weight to
Sanofi’s evidence of synergistic effects for the combination, however the
court found that those contentions, which included evidence that
Tarka® was longer acting, more effective than a separate dosage, more
effective in African American patients, and reduced the incidence of
cardiac events, more than other compounds, the court did not give this
much weight because the embodiment was narrower than the claims of
110
the invention.
B. Application to Formulations
Another questionable application of the lead compound analysis is
its application to patents on different chemical formulations. A patent
105. See id. at *5 (“In determining whether a preliminary injunction should issue, we
apply the four factor test set forth by the Supreme Court. In general, a plaintiff seeking a
preliminary injunction must establish [1] that he is likely to succeed on the merits, [2] that he
is likely to suffer irreparable harm in the absence of preliminary relief, [3] that the balance of
equities tips in his favor, and [4] that an injunction.”) (quoting Winter v. NRDC, Inc., 129 S.
Ct. 365, 374 (2008)).
106. Id. at *8 (quoting Takeda Chem. Ind., Ltd. v. Alphapharm Pty., Ltd., 492 F.3d
1350, 1357 (Fed. Cir. 2007)).
107. Id. at *8–*10.
108. Id. at *12.
109. Id.
110. Id. at *14.
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on a chemical formulation is used widely for pharmaceutical patents to
describe both the inactive and active ingredients of a drug, along with
their relative compositions. Patents on chemical formulations are also
prevalent in many other areas not limited to formulations. A
formulation patent for a pharmaceutical was at issue in Unigene
111
112
Laboratories v. Apotex. Unigene was the owner of the ‘392 patent
for nasal calitonin formulations. The patent claimed a pharmaceutical
composition of calcitonin, citric acid, phenyl ethyl alcohol, benzyl
113
alcohol, and polysorbate in a specified concentration.
The patent
reported that the concentration conferred unexpected and beneficial
114
properties when administered in that concentration.
After Apotex
submitted an Abbreviated New Drug Application (ANDA) for a
generic of the commercial embodiment of the patent Fortical®,
115
Unigene sued, asserting artificial infringement.
Apotex argued that
the patent was invalid as obvious and that the claim at issue would have
116
been obvious based upon a large number of prior art teachings.
Apotex also asserted that obviousness could be based on a lead
compound, Miacalcin, a compound similar to salmon calcitonin which
consisted of a formulation including Miacalcin in about the same
117
composition as the patent reported for salmon calcitonin.
While
118
ultimately rejecting Apotex’s obviousness argument, the court applied
the lead compound analysis by concluding that Micalin was a lead
119
compound for the development of similar drugs.
C. Lead Compound Analysis and the Requirements of KSR
Beyond its questionable applications, the lead compound
obviousness analysis prompts another important question, that is, does
anything warrant this special test after KSR? The lead compound
analysis began before the Supreme Court cautioned against rigid and
120
inflexible approaches toward obviousness.
The Supreme Court’s
landmark KSR decision came down in 2007, but the Federal Circuit
111.
112.
113.
114.
115.
116.
117.
118.
119.
120.

Unigene Labs. v. Apotex, No. 06-CV-5572, 2009 WL 2762706 (S.D.N.Y.).
U.S. Patent No. 6,440, 392, Issued Aug. 27, 2002.
Id. at Col 6, l. 35–37.
Id. at Col. 7, l 20–22.
Unigene Labs., 2009 WL 2762706.
Id. at *7.
Id.
Id. at *15.
Id. at *7 n.11.
See KSR Int’l Co. v. Teleflex, 550 U.S. 398, 415 (2007).
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cases before and after KSR show that the Federal Circuit’s analysis has
changed little after KSR.
In KSR v. Teleflex, a patent licensee alleged that a competitor
infringed the licensed patent for an accelerator pedal assembly for
121
vehicles.
Automobile gas pedals control the rate at which gasoline
122
and air enter the engine.
In the 1970s, these petals were improved
such that the pedal could be adjusted within an automobile’s footwell to
123
The prior art included adjustable pedal
accommodate small drivers.
assemblies where both the pedals and the pivot points moved when the
driver adjusted the footwell. Regardless of the adjustability, pedals can
interact with the throttle in two ways, either by a mechanical link or by a
computer that detects the position of the petal and transmits that
124
information to the throttle electronically. The Rixon patent revealed
an adjustable pedal assembly with an electronic sensor mounted in the
125
footpad of each pedal. The wires connecting the electronic sensors to
the computer controlled throttle in the Rixon disclosure, however, were
known to chafe as a result of the pedal arm’s movement.
The patent at issue in KSR was the Engelgau patent which improved
on the Rixon patent. It disclosed a position-adjustable pedal assembly
with an electronic pedal position sensor attached to the support
assembly that allowed the sensor to remain in a fixed position while the
126
driver adjusts the pedal.
Not knowing of the Engelgau disclosure,
General Motors Corporation asked KSR to supply adjustable pedal
127
systems.
Teleflex then notified KSR of the Engelgau patent and
sought a licensing fee. After negotiaiations broke down, the KSR
128
challenged the patent’s validity on grounds of obviousness.
After the district court granted summary judgment in favor of KSR,
holding that the patent was invalid as obvious, the Federal Circuit
129
overturned.
The Federal Circuit, in overturning the decision noted
130
the powerful attraction of hindsight bias in the obviousness analysis.

121. Teleflex, Inc. v. KSR Int’l Co., 298 F. Supp. 2d. 581 (E.D. Mich. 2003).
122. Daniel Becker, KSR v. Teleflex: How “Obviousness” has Changed, 4 DUKE J.
CONST. L. & PP SIDEBAR 45, 46 (2009).
123. Id.
124. Id. at 46–47.
125. U.S. Patent No. 5,819,593 (filed Aug. 17, 1995).
126. U.S. Patent No. 6,109,241 (filed Jan. 26, 1999).
127. KSR Int’l Co. v. Teleflex, 550 U.S. 398, 410 (2007).
128. Teleflex, Inc. v. KSR Int’l Co., 298 F. Supp. 2d. 581, 587 (E.D. Mich. 2003).
129. Teleflex v. KSR Int’l Co., 119 F. App’x 282, 283 (Fed. Cir. 2005).
130. Id. at 288.
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The Federal Circuit then noted that the best way to avoid the distortions
of hindsight bias was to apply the court’s teaching-suggestionmotivation test, which requires a court to make a specific finding of
some teaching suggestion or motivation in the prior art to combine
131
previous elements in the way asserted to be obvious.
132
The Supreme Court disagreed. The Supreme Court disagreed with
several aspects of the Federal Court’s decision, but the main holding
was that the Federal Circuit’s obviousness analysis was overly rigid and
formulaic, and could not encompass the flexibility needed for an
133
obviousness analysis. In overturning the Federal Circuit’s contention
that the person of ordinary skill in the art would not have looked to a
patent designed to solve a different problem, the court noted that the
person of ordinary skill was also a person of ordinary creativity who
could look at patents outside of the exact problem the person was trying
to solve.
Further, the court repudiated the Federal Circuit’s contention that
proof that a combination would have been obvious to try could never be
sufficient to establish obviousness. To the contrary, the court held that
when there are “a finite number of identified, predictable, solutions,” a
person attempting to solve a problem will likely first try “known options
within his or her technical grasp” and that the results obtained from this
134
process, are merely those of “ordinary skill and common sense.”
KSR v. Teleflex was immediately recognized as a dramatic change to
135
the obviousness landscape. After KSR, the bright line rule was that if
there was no teaching, motivation, or suggestion in the prior art hinting
at combining elements in the way the patent combined them, that the
patent could not be invalidated as obvious. Not only did the Supreme
Court abolish the TSM test as the exclusive test for obviousness, the
court emphasized that the correct approach to determining
nonobviousness could not generally be contained in a rigid formula,
136
rather the test was to be “expansive and flexible.”
The Court also
gave some additional features to the person of ordinary skill in the art.
Now the PHOSITA has been given creativity and common sense to
further heighten the standard for nonobviousness.

131.
132.
133.
134.
135.
136.

Id. at 290.
KSR Int’l Co. v. Teleflex, 550 U.S. 398, 415 (2007).
Id.
Id.
Becker, supra note 122, at 55.
KSR Int’l Co., 550 U.S. at 415.
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Federal Circuit decisions employing the lead compound analysis
have alluded to the doctrine’s consistency with KSR, but that
consistency is questionable. For example, the Federal Circuit in
Takeda, a post-KSR case, squared the lead compound analysis with
KSR’s directive to identify “a reason that would have prompted a
person of ordinary skill in the relevant field to combine the elements in
137
the way the claimed new invention does.” However, a closer look at
KSR reveals the inconsistency of these two tests: KSR did not contain
any rule concerning the motivation of the selection of the primary prior
art references. This additional hurdle is significant because it forces a
party seeking to prove obviousness to demonstrate rationale for the
prior art where that same showing would not be required in a
mechanical context. Moreover, the statutory interpretation where
obviousness means one thing in one situation, and another in a different
context is questionable. The Supreme Court has previously warned
138
against applying the same statutory text differently in different cases.
III. TAKEAWAYS
Understanding the nuances of the lead compound analysis and how
it is likely to be applied by both the Federal Circuit and by district
courts is important both in litigation challenging a patent’s
nonobviousness of a chemical compound and for creating strong patent
portfolios. Furthermore, an understanding of where the lead compound
analysis fails to capture the realities of drug discoveries can be useful in
creating policies and practices for protecting chemical innovations
where the lead compound analysis is unhelpful.
One important take away from the cases is that the lead compound
analysis greatly favors the patentee in most situations. A party
challenging the obviousness of a chemical compound faces an uphill
battle in showing both that there was a structurally similar compound
that would have been considered a lead compound, and that there was a
motivation to modify the compound.
An important factor to understand for the lead compound analysis is
what exactly a lead compound is and is not, as the court’s conception is
137. Takeda Chem. Ind., Ltd. v. Alphapharm Pty., Ltd., 492 F.3d 1350, 1356–57 (Fed.
Cir. 2007) (citing KSR, 550 U.S. at 418.).
138. See U.S. v. Santos, 553 US 507, 522–23 (2008) (“[T]he meaning of words in a
statute cannot change with the statute’s application. To hold otherwise, would render every
statute a chameleon and would establish within our jurisprudence . . . the dangerous principle
that judges can give the same statutory text different meanings in different cases.”) (citations
and quotation marks omitted).
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likely more narrow than a common sense understanding of the term
lead compound. While courts have been willing to say that there could
be more than one lead compound, courts have generally assumed that
there will be a small number in order for the choices to be sufficiently
finite. Thus, a party challenging a compound’s obviousness is really
created with a Hobson’s choice. They can assert that the compound is
obvious based on several lead compounds, but if they assert too many,
the court may decide that the choices were too numerous for any one
compound to be considered lead.
While there is no bright line for how many lead compounds there
could be, the cases provide some illustrations of where the line may be
from cases where courts have found a chemical compound obvious. The
court’s main consideration in looking at the number of potential leads
comes from language in KSR that an important consideration for
obviousness is when there are a “finite number of identified, predictable
139
solutions.” The court has considered a compound lead when there are
only a small number of other compounds. In Altana Pharma v. Teva,
for example, a compound was considered a lead compound when it was
140
disclosed along with eighteen similar compounds. On the other end of
the spectrum, when there are thousands of options, the court is unlikely
to find a compound to be a lead compound. For example, in Takeda,
where the prior art reference disclosed millions of compounds including
the compound at issue, the compound was not considered a lead
141
compound.
Another important issue for parties considering litigation over a lead
compound is when the compound is part of a formulation or a
combination drug. Thus far, there has been no clarity offered by the
Federal Circuit on whether the lead compound analysis can be used in
combination drugs or not or what would be considered the lead
compound. The district court cases show that the court may be willing
142
to consider the structural similarity of components of mixtures.
Neither of the district court cases paint a clear picture of how the lead
compound analysis might be used in conjunction with other elements.
For example, even if the prima facie case was met for one component of
139. KSR Int’l Co., 550 U.S. at 421.
140. Altana Pharma AG v. Teva Pharm. USA, Inc., 566 F.3d 999, 1008 (Fed. Cir.
2007).
141. Takeda, 492 F.3d at 1357 (Fed. Cir. 2007)
142. See, e.g., Sanofi-Aventis Deutschland GMBH v. Glenmark Pharms., No. 07-CV5855 (DMC), 2010 WL 2428561 (D.N.J.); Unigene Labs. v. Apotex, No. 06-CV-5572, 2009
WL 2762706 (S.D.N.Y.).
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a mixture, how would that affect the consideration of whether the
combination of that element with other elements was met? Will courts
consider the structural similarity separately from the combination of
elements? Is there any precedent for such a bifurcation in the
obviousness analysis? These questions remain unanswered.
Finally, what can be done when the prior art does disclose a lead
compound? For drugs that are developed based off a linear approach,
patent protection may be available to those who show unexpected
results, or teaching away. The lead compound approach seemlingly
failse to take into consideration situations where the sythesis is difficult
or unavailable. For example, in the case of gemcitibine, gemcitibine was
recognized early on as a compound of particular relevance, but due to
143
its functionality, the compound was not tested.
The proposals had
only failed because the compound proved so difficult to synthesize, and
the lead compound analysis does not take this into consideration.
Claims to the compound per se compound would be difficult to defend
from a challenge under the current application of the lead compound
analysis. However, it seems unfitting that the availability of synthetic
routes does not seem to be important to the lead compound analysis.
IV. CONCLUSION
Understanding the development and application of the Federal
Circuit’s lead compound approach is to chemical obviousness is
important for both prosecution and litigation practitioners in the
chemical arts. Understanding the Federal Circuit’s test, and how it has
been used can be predictive in evaluating the strength of protection
which may be available to claims to a compound per se, and even, to
mixtures of componds. Further, in light of KSR, future litigation may
focus on whether the analysis is too rigid, and the Federal Circuit’s
response may be important in the continuing development of the case
law on obviousness.

143.

Eli Lilly & Co. v. Sicor Pharm., 705 F. Supp. 2d, 971 (S.D. Ind. 2010).

